UP!
| 2016-06-12 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-06-12 | Reiterated Rating | FBR & Co | Hold | |
| 2016-05-06 | Reiterated Rating | Wedbush | Neutral | $4.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | $8.00 |
| 2016-04-12 | Reiterated Rating | Leerink Swann | Outperform | $11.00 |
| 2016-04-11 | Reiterated Rating | Oppenheimer | Market Perform | |
| 2016-04-11 | Reiterated Rating | Oppenheimer Holdings Inc. | Market Perform | |
| 2016-04-07 | Reiterated Rating | Wedbush | Neutral | $4.00 |
| 2016-03-28 | Lower Price Target | Leerink Swann | Outperform | $18.00 to $15.00 |
| 2016-03-20 | Downgrade | JMP Securities | Hold | |
| 2016-03-17 | Reiterated Rating | FBR & Co. | Market Perform | |
| 2016-02-26 | Downgrade | JMP Securities | Mkt Outperform to Market Perform | |
| 2016-02-26 | Lower Price Target | Leerink Swann | Outperform | $17.00 to $11.00 |
| 2016-02-26 | Lower Price Target | Cowen and Company | Outperform | $18.00 to $8.00 |
| 2016-02-26 | Boost Price Target | FBR & Co. | Mkt Perform | $6.00 to $10.00 |
| 2016-01-26 | Upgrade | Citigroup Inc. | Neutral to Buy | |
| 2015-12-10 | Reiterated Rating | Wedbush | Neutral | $7.00 |
| 2015-12-01 | Reiterated Rating | Oppenheimer | Hold | |
| 2015-11-06 | Upgrade | Wedbush | Underperform to Neutral | $7.00 |
| 2015-10-06 | Reiterated Rating | Leerink Swann | Outperform | |
| 2015-09-28 | Upgrade | Oppenheimer | Underperform to Market Perform | $6.00 |
| 2015-09-23 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-09-15 | Downgrade | FBR & Co. | Hold | |
| 2015-09-15 | Reiterated Rating | Oppenheimer | Underperform | $7.00 to $6.00 |
| 2015-09-15 | Reiterated Rating | Cowen and Company | Buy | $24.00 to $18.00 |
| 2015-09-15 | Downgrade | Citigroup Inc. | Buy to Neutral | $20.00 to $8.00 |
| 2015-09-14 | Reiterated Rating | Leerink Swann | Buy | $20.00 to $17.00 |
| 2015-09-14 | Lower Price Target | FBR & Co. | Market Perform | $16.00 to $10.00 |
| 2015-09-09 | Lower Price Target | Oppenheimer | Underperform | $8.00 to $7.00 |
| 2015-08-22 | Reiterated Rating | FBR & Co. | Hold | $16.00 |
| 2015-08-22 | Reiterated Rating | Janney Montgomery Scott | Buy | |
| 2015-08-21 | Reiterated Rating | Wedbush | Underperform | $5.00 to $7.00 |
| 2015-08-17 | Reiterated Rating | Cowen and Company | Outperform | $24.00 |
| 2015-08-11 | Initiated Coverage | FBR & Co. | Market Perform | $16.00 |
| 2015-08-10 | Reiterated Rating | Oppenheimer | Underperform | $8.00 |
| 2015-08-07 | Boost Price Target | JMP Securities | Market Outperform | $34.00 |
| 2015-07-16 | Boost Price Target | Leerink Swann | Outperform | $15.00 to $20.00 |
| 2015-07-06 | Downgrade | Oppenheimer | Market Perform to Underperform | $8.00 |
| 2015-06-10 | Initiated Coverage | Citigroup Inc. | Buy | $20.00 |
| 2015-04-15 | Initiated Coverage | Janney Montgomery Scott | Buy to Buy | $16.00 |
| 2015-02-27 | Lower Price Target | Leerink Swann | Outperform | $18.00 to $15.00 |
| 2015-02-24 | Reiterated Rating | Oppenheimer | Market Perform | |
| 2015-02-23 | Downgrade | Wedbush | Sell | $7.00 |
| 2014-10-31 | Initiated Coverage | Oppenheimer | Market Perform | |
| 2014-05-27 | Lower Price Target | FBR & Co. | Outperform | $17.00 to $16.00 |
| 2014-05-09 | Lower Price Target | Leerink Swann | Outperform | $24.00 to $18.00 |
| 2014-05-06 | Lower Price Target | Wedbush | $10.00 to $7.00 | |
| 2014-02-21 | Downgrade | Ladenburg Thalmann | Buy to Neutral | $15.50 |
| 2014-02-05 | Downgrade | Wedbush | Neutral to Underperform | |
| 2014-01-23 | Boost Price Target | Leerink Swann | $17.00 to $19.00 | |
| 2013-11-11 | Boost Price Target | Ladenburg Thalmann | Buy | $12.00 to $15.50 |
| 2013-11-11 | Boost Price Target | Janney Montgomery Scott | Buy | $13.00 to $17.00 |
| 2013-10-30 | Initiated Coverage | FBR & Co. | Outperform | $17.00 |
| 2013-10-29 | Boost Price Target | Leerink Swann | Outperform | $14.00 to $17.00 |
| 2013-09-25 | Downgrade | Oppenheimer | Outperform to Market Perform | |
| 2011-09-16 | Initiated | Oppenheimer | Outperform | $11 |
| 2011-07-25 | Reiterated | JMP Securities | Mkt Outperform | $7 to $12 |
| 2011-07-11 | Reiterated | Ladenburg Thalmann | Buy | $5 to $7.25 |
| 2011-05-12 | Initiated | Canaccord Genuity | Buy | $10 |
| 2011-05-05 | Initiated | Global Hunter Securities | Buy | $6 |
| 2010-01-28 | Initiated | C.K. Cooper | Hold | $2.65 |
| 2016-06-12 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-06-12 | Reiterated Rating | FBR & Co | Hold | |
| 2016-05-06 | Reiterated Rating | Wedbush | Neutral | $4.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | $8.00 |
| 2016-04-12 | Reiterated Rating | Leerink Swann | Outperform | $11.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In RPTP 1 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| MANAGED ACCOUNT ADVISORS LLC | 12695 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Hyperion Trading Segregated Portfolio | 9.49% (5954700) | RPTP / |
| STARR CHRISTOPHER M Chief Executive Officer | 1.14% (714395) | RPTP / |
| Smith Julie EVP, Strategy and COO | 0.16% (102129) | BOLD / EXEL / RPTP / |
| Daley Thomas E President, Raptor Therapeutics | 0.12% (74719) | RPTP / |
| Bruhn Suzanne Louise | 0.09% (56767) | AGLE / QLTI / RPTP / |
| Gould Ashley C. SVP Gen Counsel-CorpGovernance | 0.07% (45003) | HPTX / RPTP / |
| Happel David Chief Commerical Officer | 0.05% (29670) | RPTP / |
| Polu Krishna R Chief Medical Officer | 0.04% (23781) | RPTP / |
| Smith Michael P Chief Financial Officer | 0.04% (22607) | RPTP / ZGNX / |
| Erbez Georgia Chief Financial Officer | 0.03% (16100) | RPTP / ZSAN / |
| Anderson Raymond | 0.02% (15025) | RPTP / |
| Keltner Llew | 0.02% (15025) | RPTP / |
| FRANKLIN RICHARD L | 0.02% (15025) | RPTP / |
| LAPOINTE ANTHONY GREGG | 0.02% (10422) | CYTX / RIGL / RPTP / SCLN / SNGX / |
| GEMAYEL GEORGES | 0.02% (10422) | MNTA / NPSP / RPTP / SUPN / |
| SAGER ERICH | 0.01% (4005) | RPTP / |
UM